Scarica l'app Stockscreener
180.06
1.28%
-2.215
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance Singapore
AstraZeneca PLC Stock (US6549022043): Obesity Drug Elecoglipron Heads Into Phase 3 As Shares Climb - AD HOC NEWS
ASTRAZENECA : Deutsche Bank maintains a Sell rating - marketscreener.com
ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations - Citeline News & Insights
Jim Cramer on AstraZeneca: “On Track to Hit the Ambitious Long-Term Financial Targets” - Yahoo Finance
Hansa Biopharma appoints Head of Business Development from AstraZeneca - marketscreener.com
AstraZeneca advances oral GLP-1 elecoglipron into phase 3 - MSN
AstraZeneca PLC stock (US6549022043): obesity drug data and pipeline momentum keep investors alert - AD HOC NEWS
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - Benzinga
Functional genomics and AI drive novel target discovery at AstraZeneca - Select Science
ASTRAZENECA : JP Morgan remains its Buy rating - marketscreener.com
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA - Clinical Trials Arena
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth - GlobeNewswire Inc.
AstraZeneca Advances Obesity, Diabetes Medication Elecoglipron to Phase 3 Trial - marketscreener.com
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
NYLIM VP Income Builder Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
BofA reiterates Buy on AstraZeneca stock, cites adjuvant trial outlook By Investing.com - Investing.com South Africa
AstraZeneca progresses elecoglipron after positive phase IIb results - London South East
Why is CAMBRIA-1 emerging as AstraZeneca’s key breast cancer catalyst? - Investing.com Nigeria
ASTRAZENECA : Jefferies remains its Buy rating - marketscreener.com
AstraZeneca Gears Up for Phase 3 Trial of Weight-loss Drug - marketscreener.com
IAMS WEALTH MANAGEMENT, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results - GuruFocus
Elecoglipron cut nearly 12% of body weight in study, AstraZeneca says - AOL.com
AstraZeneca unveils data behind Phase III-bound oral GLP-1 - FirstWord Pharma
AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results - Investing.com Nigeria
AstraZeneca obesity pill shows 10.5% weight loss in trial By Investing.com - Investing.com UK
AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio - marketscreener.com
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial - marketscreener.com
AstraZeneca advances weight-loss pill to take aim at obesity leaders - Financial Times
ADA 2026: AstraZeneca Advances Oral GLP-1 Elecoglipron Into Phase III After Positive Trial Data - Citeline News & Insights
AstraZeneca plc stock (GB0009895292): Oncology pipeline, obesity push and latest trial updates in fo - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential - DirectorsTalk Interviews
AstraZeneca hails phase 3 trial results of inhibitor Ultomiris - London South East
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
AstraZeneca warns it could delay Europe drug launchesFT - marketscreener.com
PRESS: AstraZeneca warns it could delay Europe drug launchesFT - London South East
AstraZeneca chief warns group could withhold new drugs in Europe - Financial Times
AstraZeneca Broadens US Growth Push - marketscreener.com
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca plc stock (GB0009895292): Share price edges higher after 3.1% move and valuation focus - AD HOC NEWS
AstraZeneca (AZN) Stock Gains 3.1% as Bernstein Highlights Overlooked Non-Oncology Potential - parameter.io
AstraZeneca (AZN) Stock: Bernstein's £186 Target Highlights Overlooked Non-Oncology Potential - MoneyCheck
AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment - Blockonomi
AstraZeneca (AZN) Stock: Bernstein Sees 37% Upside as Non-Oncology Gets Ignored - CoinCentral
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History - Yahoo Finance
Bernstein: Why AstraZeneca’s biggest growth opportunity is being overlooked By Investing.com - Investing.com Nigeria
Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca - marketscreener.com
Why is AstraZeneca trending right now - Kalkine Media
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 T - GuruFocus
AstraZeneca Advances New Fixed-Dose Cholesterol Pill Into Phase I: What Investors Should Watch - TipRanks
AstraZeneca advances Thursday, outperforms market - MarketWatch
AstraZeneca plc stock (GB0009895292): oncology growth and sector backdrop ahead of next earnings - AD HOC NEWS
AstraZeneca (AZN) CEO awarded 101,495 shares on AZPSP vesting - Stock Titan
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial - Yahoo
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum? - Yahoo Finance
Deutsche Bank Holds Sell Rating On AstraZeneca (LSE:AZN, NASDAQ:AZN) At 11,500p Despite Positive ASCO Data - londoninsider.co.uk
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions - Proactive financial news
AstraZeneca PLC Share PriceAZN, RNS News, Articles, Quotes, & Charts (LON:AZN) - Proactive Investors
0.28%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):